Charles Wakeford

Beneficial effects of an investigational wristband containing Synsepalum dulcificum (miracle fruit) seed oil on the performance of hand and finger motor skills in healthy subjects: A randomized controlled preliminary study

Steven Gorin, Charles Wakeford, Guodong Zhang, Elvira Sukamtoh et autres

Miracle fruit (Synsepalum dulcificum) seed oil (MFSO) contains phytochemicals and nutrients reported to affect musculoskeletal performance. The purpose of this study was to assess the safety and efficacy of a compression wristband containing MFSO on its ability to measurably improve the hand …

us (code pays fourni par la source)

Effect of Miracle Fruit (Synsepalum dulcificum) Seed Oil (MFSO®) on the Measurable Improvement of Hair Breakage in Women with Damaged Hair: A Randomized, Double-blind, Placebo-controlled, Eight-month Trial.

Del Campo R, Y Zhang, Charles Wakeford

The MFSO hair oil product is a safe and effective option for the treatment of women suffering from hair breakage and damaged hair.

us (code pays fourni par la source)

PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY

Juergen Weitz, Lisa M. Bernard, Charles Wakeford

Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients

Joshua M Waters, Wesley T. O’Neal, Kirsten White, Charles Wakeford et autres

BACKGROUND: Antiretroviral therapy that targets HIV type-1 (HIV-1) reverse transcriptase (RT) can be linked to mutations in the thumb-connection (amino acids [AA] 241-426) and RNase H (AA 427-560) domains, which could affect drug resistance. METHODS: Genotypical and statistical analyses were performed on …

us (code pays fourni par la source)

LEARNING BY DESIGN: FORMATS FOR ONLINE ENQUIRY AND PROBLEM SOLVING

Charles Wakeford

Innovative Approaches in Drug Development

Mark M. Chang, Susan Kenley, Jonca C. Bull, Yuan-Yuan H. Chiu et autres

This is the white paper on Innovative Approaches in Drug Development developed by the Biotechnology Industry Organization's (BIO) Clinical Trial Designs Workgroup. As recognized by the Food and Drug Administration's Critical Path Opportunities Report, the need to develop and apply innovative approaches …

us, de, au (code pays fourni par la source)

Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects

Ian Sanne, Herve Momméja-Marin, John E. Hinkle, John A Bartlett et autres

Human immunodeficiency virus (HIV)-infected South African patients (n=468) received blinded lamivudine or emtricitabine, stavudine, and either nevirapine or efavirenz (based on screening viral load). Baseline characteristics were analyzed in univariate and multivariate regression, to identify risk factors for hepatotoxicity (grade 3 or …

Afrique du Sud, us (code pays fourni par la source)

Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection

Laurene H. Wang, John A. Begley, R. L. St. Claire, Jeanette L. Harris et autres

Emtricitabine (FTC) is a potent deoxycytidine nucleoside analogue that was recently approved for the treatment of HIV infection. Emtricitabine is activated by intracellular phosphorylation to its 5'-triphosphate (FTC5'-TP), a competitive inhibitor of the HIV reverse transcriptase (RT). Early clinical studies incorporating pharmacokinetic-pharmacodynamic …

au (code pays fourni par la source)

Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection

Laurene H. Wang, John A. Begley, Robert L. St. Claire, Jeanette L. Harris et autres

Emtricitabine (FTC) is a potent deoxycytidine nucleoside analogue that was recently approved for the treatment of HIV infection. Emtricitabine is activated by intracellular phosphorylation to its 5'-triphosphate (FTC- 5'-TP), a competitive inhibitor of the HIV reverse transcriptase (RT). Early clinical studies incorporating …

Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected Patients

Franck S. Rousseau, Charles Wakeford, Herve Momméja-Marin, Ian Sanne et autres

We conducted a randomized, open-label, 10-day study that compared the antiretroviral activity of emtricitabine (FTC) 25, 100, and 200 mg once daily and lamivudine (3TC) 150 mg 2 times/day in 82 human immunodeficiency virus (HIV)-infected patients with virus loads 15000 and !100,000 …

gb, Afrique du Sud, us (code pays fourni par la source)

Evaluation of three commercially available HBV viral load assays

Andrea Lynn Snow, Florence T. Myrick, Charles Wakeford, Bruce J. McCreedy

us (code pays fourni par la source)

Duration of effects of isradipine during twice daily therapy in angina pectoris

Udho Thadani, Steven G. Chrysant, Jeffrey Gorwit, Thomas D. Giles et autres

us (code pays fourni par la source)